Skip to main
STTK

Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs (STTK) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Shattuck Labs is a promising biotechnology company with a strong platform technology and a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's focus on DR3 antagonism has shown promising results in clinical trials, with strong receptor occupancy and no observed DR3 agonism. The development of a half-life extended version of their lead asset and other preclinical bispecific antibodies speaks to the potential of their platform technology. The risks for their success lie in clinical and regulatory outcomes, as well as potential competition from other companies in the highly competitive space of TL1A/DR3 targeting.

Bears say

Shattuck Labs is facing several challenges, including a lack of current revenue and upcoming catalysts for their main program SL-325, which may not be enough to sustain the company in the long term. Additionally, competition in the TL1A space, potential immunogenicity issues, and doubts about the potential success of their TL1A candidates in IBD may lower investor confidence and hinder the company's growth. As a result, the negative outlook on this stock is justified.

Shattuck Labs (STTK) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shattuck Labs (STTK) Forecast

Analysts have given Shattuck Labs (STTK) a Buy based on their latest research and market trends.

According to 6 analysts, Shattuck Labs (STTK) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shattuck Labs (STTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.